La Jolla Pharmaceutical (NASDAQ:LJPC) Releases Earnings Results

La Jolla Pharmaceutical (NASDAQ:LJPCGet Rating) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.16), Fidelity Earnings reports. La Jolla Pharmaceutical had a negative return on equity of 27.07% and a net margin of 25.96%.

Shares of La Jolla Pharmaceutical stock traded up $0.15 on Tuesday, reaching $4.16. 53,235 shares of the company were exchanged, compared to its average volume of 66,331. The company has a market capitalization of $106.58 million, a price-to-earnings ratio of 7.30 and a beta of 1.94. The company has a 50-day moving average of $4.18 and a 200 day moving average of $4.30. La Jolla Pharmaceutical has a one year low of $3.40 and a one year high of $5.69.

Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new stake in shares of La Jolla Pharmaceutical in the 3rd quarter valued at about $183,000. Citadel Advisors LLC lifted its holdings in La Jolla Pharmaceutical by 37.7% during the 4th quarter. Citadel Advisors LLC now owns 61,977 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 16,959 shares during the last quarter. Northern Trust Corp boosted its position in La Jolla Pharmaceutical by 5.3% during the first quarter. Northern Trust Corp now owns 80,053 shares of the biopharmaceutical company’s stock worth $341,000 after purchasing an additional 4,047 shares during the period. State Street Corp boosted its stake in La Jolla Pharmaceutical by 4.2% in the 1st quarter. State Street Corp now owns 98,941 shares of the biopharmaceutical company’s stock valued at $422,000 after purchasing an additional 3,962 shares during the period. Finally, Bank of New York Mellon Corp increased its position in La Jolla Pharmaceutical by 4.8% during the 1st quarter. Bank of New York Mellon Corp now owns 127,084 shares of the biopharmaceutical company’s stock worth $543,000 after buying an additional 5,781 shares during the period. 97.06% of the stock is owned by institutional investors.

Separately, StockNews.com assumed coverage on La Jolla Pharmaceutical in a research note on Thursday, March 31st. They issued a “buy” rating for the company.

About La Jolla Pharmaceutical (Get Rating)

La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.

Featured Articles

Earnings History for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.